Research InterestsResearch in my laboratory focuses on chemotherapeutic drug (CDDP, 5-FU, Irinotecan)which induces cancer cell death. I am interested in molecular and/or cellular mechanism(s) of CDDP and the other chemical compounds which involve in apoptosis of mitochondria of Head and Neck cancer cell lines and application of CDDP and the compounds thereof
Feng KY, Chou JA, Yang Z. Clinical observation on the treatment of arrhythmias with Dauricine. Chin. J Cardiovasc Diseases, 12(2):265-267, 1984.
Zhou JA, Feng KY, Yang Z. Investigation of clinical effects of Dauricine in patients with arrhythmia. Chin J Clinic Pharmacol, 3(2):93-95, 1987.
Zeng WC, Yang Z. Effect of O-methyldauricine on ECG and hemodynamics in anesthetized dog. Acta Chin Pharmacol, 5(2):92-94, 1989.
Ellis MJC, Leav BA, Yang Z, Lippman M, Cullen KJ. The IGF-II/Mannose 6-phosphate receptor negatively regulates IGF-II signaling in breast cancer cells. Keystone Symposia. J Cell Biochem Supp 19A1-122, 1995.
Ellis MJC, Leav BA, Yang Z, Rasmussen A, Pearce A, Zweibel JA, Lippman ME, Cullen KJ. Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells. Mol Endocrinol, 10(3):286-297, 1996.
Yang Z, Faustino PJ, Andrews, PA, Monastra R, Rasmussen AA, Ellison C, Cullen KJ. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck. Cancer Chemother Pharmacol, 46(4):255-256, 2000.
Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res, 63(2):312-8, 2003.
Abstracts and Presentations
Ellis MJC, Leav BA, Yang Z, Cullen KJ. The IGF-II/Mannose 6-phosphate receptor negatively regulates IGF-II signaling via the IGF-I receptor in breast carcinoma cells. 86th Annual Meeting American Society of Cancer Research, Proceedings AACR, 36:Abstract 3727, 1995.
Ellis MJ, Yang Z, Rassmussen A, Arun BK, Giani C, Cullen KJ. The Mannose 6-Phosphate/Insulin-like Growth Factor-II (M6P/IGF2R), a putiative breast cancer tumor suppressor gene. 10th International Congress of Endocrinology, San Francisco, Abstract OR57-8, 1996.
Ellis MJ, Yang Z, Schumaker L, Pearce A, Arun BK, Oates A. Suppression of rhabdmyosarcoma cell growth by mannose 6-phosphate/insulin-like growth Factor-II receptor (M6P/IGF2R) overexpression. 88th Annual Meeting, American Society of Cancer Research, Proceedings AACR, 38:Abstract 473, 1997.
Sasner M, Yang Z, Buonano A. Development analysis of erbB receptor expression in the rat cerebellum. 27th Annual Meeting, American Society of Neuroscience, 23:Abstracts (Part 1), New Orleans, 1997.
Shiga H, Rasmussen AA, Yang Z, Langmaker M, Baylor A, Lee M, Sessions RB, Cullen KJ. Prognostic value of glutahione s-transferase Pi, P53 and thymidylate synthase for cisplatin based chemotherapy in head and neck. Head Neck, 20(5):Abstract 476, 1998.
Yang Z, Faustino PJ, Andrews PA, Monastra AA, Rasmussen AA, Ellison C, Cullen KJ. Cisplatin/DNA adduct formation is inversely correlated with cisplatin sensitivity and intracellular glutathione levels in head and neck squamous cancer cell lines. Head Neck, 20(5):Abstract 484, 1998.
Kevin Cullen, Zejia Yang, Lisa Schumaker, Ellie Zuhoski, Merrill Egorin. Direct action on mitochondria, not nuclear DNA, mediates cisplatin induced apoptosis in head and neck cancer. 96th Annual Meeting American Society of Cancer Research, Abstract #1693, 2005.